A detailed history of Nuveen Asset Management, LLC transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 271,613 shares of APLT stock, worth $2.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
271,613
Holding current value
$2.25 Million
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$4.04 - $6.37 $1.1 Million - $1.73 Million
271,613 New
271,613 $1.27 Million
Q2 2022

Aug 15, 2022

SELL
$0.76 - $2.64 $40,918 - $142,137
-53,840 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$1.48 - $6.22 $12,087 - $50,798
-8,167 Reduced 13.17%
53,840 $98,000
Q4 2021

Feb 14, 2022

SELL
$8.77 - $18.29 $109,265 - $227,875
-12,459 Reduced 16.73%
62,007 $555,000
Q3 2021

Nov 12, 2021

SELL
$13.54 - $22.06 $230,085 - $374,865
-16,993 Reduced 18.58%
74,466 $1.24 Million
Q2 2021

Aug 16, 2021

BUY
$14.05 - $25.04 $426,839 - $760,715
30,380 Added 49.74%
91,459 $1.9 Million
Q1 2021

May 17, 2021

BUY
$16.57 - $28.65 $44,805 - $77,469
2,704 Added 4.63%
61,079 $1.15 Million
Q4 2020

Feb 16, 2021

BUY
$15.44 - $24.23 $114,039 - $178,962
7,386 Added 14.49%
58,375 $1.29 Million
Q3 2020

Nov 16, 2020

SELL
$19.43 - $35.36 $135,543 - $246,671
-6,976 Reduced 12.03%
50,989 $1.06 Million
Q2 2020

Aug 14, 2020

BUY
$29.41 - $51.23 $612,169 - $1.07 Million
20,815 Added 56.03%
57,965 $2.1 Million
Q1 2020

May 14, 2020

BUY
$19.54 - $55.47 $529,201 - $1.5 Million
27,083 Added 269.03%
37,150 $1.21 Million
Q4 2019

Feb 14, 2020

BUY
$10.16 - $28.14 $102,280 - $283,285
10,067 New
10,067 $275,000

Others Institutions Holding APLT

About Applied Therapeutics Inc.


  • Ticker APLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,700
  • Market Cap $397M
  • Description
  • Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...
More about APLT
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.